Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04598399
Other study ID # PHRCN/2018/AL-01
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 20, 2021
Est. completion date November 2025

Study information

Verified date January 2024
Source Centre Hospitalier Universitaire de Nimes
Contact Amandine Luquiens
Phone 04.66.68.69.98
Email Amandine.luquiens@chu-nimes.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Alcohol use disorder (AUD) is the second highest preventable cause of death in France. Only 3% of patients are prescribed approved drugs for reducing alcohol consumption or maintenance of abstinence. Increasing evidence supports the efficacy of psychotherapies such as cognitive and behavioral therapies (CBT) in AUD. However, some patients are resistant to CBT and the positive effects of CBT could wane over time, resulting in mid- and long-term relapses. Mindfulness practice is increasingly widespread in the United States and its efficacy in various fields appears very promising. The study investigators hypothesize that the Mindfulness Based Relapse Prevention (MBRP) program will be more efficient than a relaxation/meditation without guidance control program in AUD.


Recruitment information / eligibility

Status Recruiting
Enrollment 168
Est. completion date November 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Having a moderate to severe alcohol use disorder according to DSM 5 criteria. - The last drink must have been consumed at most in the last 60 days before the pre-inclusion visit. The patient must have had at least 1 HDD during the last drinking period Exclusion Criteria: - Severe depression (Beck Depression Inventory> 30) - Schizophrenic disorder, - Current maniac or hypomaniac episode, - Patient with dementia or severe cognitive impairment that would prevent him/her from following the course of a session, as judged by the clinician. - Insufficient French understanding to complete the questionnaires - Pregnant or breastfeeding woman - Absence of social security regimen - Other mindfulness-based structured therapies - Refusal to sign the written consent. • The patient is under safeguard of justice or state guardianship

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Mindfulness Based Relapse Prevention
7 x 60-120 minute sessions with different themes: Automatic pilot/triggers/relapse/high-risk situations/ mindfulness in daily life. There will be a welcoming time, with a focus on at-home practice and difficulties, a theoretical presentation of new concepts, practical meditation exercises and a debriefing.
Relaxation/ meditation
7 x 60-120 minute sessions each with a different sound from nature with unguided, closed relaxation group with a maximum of 12 participants

Locations

Country Name City State
France Ssra Les Eumenides Angers
France Hôpital Corentin-Celton Issy-les-Moulineaux
France CHU de Nantes Nantes
France CHU de Nimes Nîmes
France Hopital Fernand Widal Paris
France Hopital Des 4 Villes Sèvres
France Hopital Paul Brousse Villejuif

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nimes

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Reduction in number of heavy drinking days (HDD) over previous 4 weeks, between the last drinking period at inclusion and 6 months. Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day. 6 months
Secondary Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 3 months between groups Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day. 3 months
Secondary Change in number of heavy drinking days (HDD) during the last 4 weeks, between the last drinking period at inclusion and 12 months between groups Alcohol Time Line Follow Back (TLFB) where a HDD = consummation of 4+ (for women) or 5+ (for men) drinks per day. 12 months
Secondary Change in 4-week total alcohol consumption since baseline number of drinks (1 glass = 1 unit according to grams alcohol) 3 months
Secondary Change in 4-week total alcohol consumption since baseline number of drinks (1 glass = 1 unit according to grams alcohol) 12 months
Secondary Change in frequency of craving since baseline version F of craving experience questionnaire (CEQ-F) 3 months
Secondary Change in frequency of craving since baseline version F of craving experience questionnaire (CEQ-F) 6 months
Secondary Change in frequency of craving since baseline version F of craving experience questionnaire (CEQ-F) 12 months
Secondary Change in strength of craving since baseline version S of craving experience questionnaire (CEQ-S) 3 months
Secondary Change in strength of craving since baseline version S of craving experience questionnaire (CEQ-S) 6 months
Secondary Change in strength of craving since baseline version S of craving experience questionnaire (CEQ-S) 12 months
Secondary Anxiety at baseline Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety Baseline
Secondary Change in anxiety since baseline Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety 3 months
Secondary Change in anxiety since baseline Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety 6 months
Secondary Change in anxiety since baseline Beck Anxiety Inventory depression (BAI): 21-item self-assessment scale assessing anxiety 12 months
Secondary Depression at baseline Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms Baseline
Secondary Change in depression since baseline Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms 3 months
Secondary Change in depression since baseline Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms 6 months
Secondary Change in depression since baseline Beck Depression Inventory (BDI): 21 items assessing the presence and severity of depressive symptoms 12 months
Secondary Change in quality of life since baseline Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire 3 months
Secondary Change in quality of life since baseline Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire 6 months
Secondary Change in quality of life since baseline Alcohol Quality of Life Scale (AQoLS): 34-item patient-reported questionnaire 12 months
Secondary Emotion regulation at baseline Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). Baseline
Secondary Change in emotion regulation since baseline Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). 3 months
Secondary Change in emotion regulation since baseline Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). 6 months
Secondary Change in emotion regulation since baseline Emotion Regulation Questionnaire (ERQ): 10-item scale designed to assessing Cognitive Reappraisal and Expressive Suppression on a 7-point Likert-type scale ranging from 1 (strongly disagree) to 7 (strongly agree). 12 months
Secondary Difficulties regulating emotion at baseline Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS Baseline
Secondary Changes in difficulties regulating emotion since baseline Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS 3 months
Secondary Changes in difficulties regulating emotion since baseline Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS 6 months
Secondary Changes in difficulties regulating emotion since baseline Difficulties in Emotion Regulation scale (DERS -Impulse): items 3, 14, 19, 24R, 27, 32 from DERS 12 months
Secondary Changes in impulsivity since baseline Impulsive behavior scale (UPPS-P): 20-item self-assessment scale 3 months
Secondary Impulsivity at baseline Impulsive behavior scale (UPPS-P): 20-item self-assessment scale Baseline
Secondary Changes in impulsivity since baseline Impulsive behavior scale (UPPS-P): 20-item self-assessment scale 6 months
Secondary Changes in impulsivity since baseline Impulsive behavior scale (UPPS-P): 20-item self-assessment scale 12 months
Secondary Changes in coping mechanism brief COPE questionnaire: 14 scales including 2 items (28 items in total) 3 months
Secondary Coping mechanism at baseline brief COPE questionnaire: 14 scales including 2 items (28 items in total) Baseline
Secondary Changes in coping mechanism brief COPE questionnaire: 14 scales including 2 items (28 items in total) 6 months
Secondary Changes in coping mechanism brief COPE questionnaire: 14 scales including 2 items (28 items in total) 12 months
Secondary Cognitive impairment Montreal Cognitive Assessment (MoCA) Baseline
Secondary Initial mindfulness Five Facets Mindfulness Questionnaire (FFMQ): 39-item self-assessment tool measuring 5 factors of mindfulness Baseline
Secondary Number of meditation sessions per week over the last 4 weeks Month 6
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04927364 - Examining the Effectiveness of Deep TMS in Veterans With Alcohol Use Disorder N/A
Active, not recruiting NCT04618653 - Comprehensive Process Model of AA-related Behavior Change
Recruiting NCT05471154 - Non-invasive Brain Stimulation of the Prefrontal Cortex in Substance Use Disorders N/A
Completed NCT05021640 - Study of DCR-AUD in Healthy Volunteers Phase 1
Not yet recruiting NCT05064228 - Mobile Rewarding Activity Centered Treatment N/A
Completed NCT04958655 - Mental Imagery Intervention for Alcohol Craving N/A
Completed NCT05252221 - Alcohol Telemedicine Consultation in Primary Care (ATC) N/A
Completed NCT06108115 - Smartphone-Based Intervention for Sleep Disturbance in Individuals Recovering From Alcohol Use Disorder N/A
Not yet recruiting NCT06303778 - Combining a Smartphone App With Medications to Manage Heavy Drinking N/A
Completed NCT04639895 - Cognitive Rehabilitation Through Personalized Virtual Reality and Paper-and-pencil Interventions in the Alcohol Use Disorder Treatment. N/A
Completed NCT02911285 - NAC for Treating Comorbid PTSD and SUD Phase 2
Completed NCT04827056 - Effect of Sublingual Formulation of Dexmedetomidine HCl (BXCL501) - Alcohol Interaction Study Phase 1
Completed NCT04974645 - Pilot: Digital Therapeutic vs Education for the Management of Problematic Substance Use N/A
Recruiting NCT05992272 - Cue Effects in Human Addiction: Pavlovian to Instrumental Transfer
Completed NCT04229095 - Medication Development in Alcoholism: Suvorexant Versus Placebo Phase 2
Recruiting NCT05534568 - The Oklahoma Parent-Child Assistance Program N/A
Completed NCT04925570 - The Anchor Study: Digitally Delivered Intervention for Reducing Problematic Substance Use Phase 2
Active, not recruiting NCT05492942 - Records for Alcohol Care Enhancement N/A
Recruiting NCT05015881 - Relationship Between Brain and Heart Glucose Metabolism in Alcohol Use Disorder Phase 2/Phase 3
Completed NCT05120856 - AAT-App Outpatient Trial N/A